Big Pharma Split Corp Class A Net Assets
Big Pharma Split Corp Class A net assets. Based on the latest financial reports, Big Pharma Split Corp Class A (PRM) has net assets worth CA$19.44 Million CAD (≈ $14.06 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CA$33.47 Million ≈ $24.21 Million USD) and total liabilities (CA$14.04 Million ≈ $10.15 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Big Pharma Split Corp Class A equity growth rate to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CA$19.44 Million |
| % of Total Assets | 58.07% |
| Annual Growth Rate | -0.28% |
| 5-Year Change | -18.46% |
| 10-Year Change | N/A |
| Growth Volatility | 29.98 |
Net Assets of Big Pharma Split Corp Class A (2017–2025)
Net assets of Big Pharma Split Corp Class A from 2017 to 2025. This chart illustrates how Big Pharma Split Corp Class A's net assets have evolved over time, based on quarterly financial data. See PRM net asset quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Big Pharma Split Corp Class A (2017–2025)
The table below shows the annual net assets of Big Pharma Split Corp Class A from 2017 to 2025. For live market cap and overall valuation, see market cap of Big Pharma Split Corp Class A.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CA$18.27 Million ≈ $13.21 Million |
+33.51% |
| 2024-12-31 | CA$13.68 Million ≈ $9.90 Million |
-13.68% |
| 2023-12-31 | CA$15.85 Million ≈ $11.47 Million |
-19.66% |
| 2022-12-31 | CA$19.73 Million ≈ $14.27 Million |
-11.93% |
| 2021-12-31 | CA$22.40 Million ≈ $16.21 Million |
+69.92% |
| 2020-12-31 | CA$13.19 Million ≈ $9.54 Million |
-19.16% |
| 2019-12-31 | CA$16.31 Million ≈ $11.80 Million |
-13.45% |
| 2018-12-31 | CA$18.84 Million ≈ $13.63 Million |
+0.89% |
| 2017-12-31 | CA$18.68 Million ≈ $13.51 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Big Pharma Split Corp Class A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 0.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Big Pharma Split Corp Class A Net Assets Breakdown (December 2025)
Big Pharma Split Corp Class A net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | CA$18.27 Million | 100.00% |
| Other Components | CA$1.00 | 0.00% |
| Total Equity | CA$18.27 Million | 100.00% |
Big Pharma Split Corp Class A Competitors by Market Cap
The table below lists competitors of Big Pharma Split Corp Class A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Brag House Holdings, Inc. Common Stock
NASDAQ:TBH
|
$14.75 Million |
|
Scan Inter PCL
BK:SCN
|
$14.75 Million |
|
PROBIOTIX HEALTH LS-05
F:X90
|
$14.76 Million |
|
High Peak Royalties Ltd
AU:HPR
|
$14.76 Million |
|
Moorim SP Co. Ltd
KQ:001810
|
$14.75 Million |
|
Close the Loop Ltd
AU:CLG
|
$14.73 Million |
|
Havsfrun Investment AB (publ)
ST:HAV-B
|
$14.73 Million |
|
Nexgram Holdings Bhd
KLSE:0096
|
$14.72 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Big Pharma Split Corp Class A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 13,682,674 to 18,268,031, a change of 4,585,357 (33.5%).
- Net income of 4,400,516 contributed positively to equity growth.
- Dividend payments of 1,507,060 reduced retained earnings.
- Share repurchases of 3,342,560 reduced equity.
- New share issuances of 3,342,557 increased equity.
- Other factors increased equity by 1,691,904.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CA$4.40 Million | +24.09% |
| Dividends Paid | CA$1.51 Million | -8.25% |
| Share Repurchases | CA$3.34 Million | -18.3% |
| Share Issuances | CA$3.34 Million | +18.3% |
| Other Changes | CA$1.69 Million | +9.26% |
| Total Change | CA$- | 33.51% |
Book Value vs Market Value Analysis
This analysis compares Big Pharma Split Corp Class A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.04x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | CA$13.73 | CA$15.53 | x |
| 2018-12-31 | CA$13.93 | CA$15.53 | x |
| 2019-12-31 | CA$13.64 | CA$15.53 | x |
| 2020-12-31 | CA$13.24 | CA$15.53 | x |
| 2021-12-31 | CA$17.38 | CA$15.53 | x |
| 2022-12-31 | CA$13.07 | CA$15.53 | x |
| 2023-12-31 | CA$13.03 | CA$15.53 | x |
| 2024-12-31 | CA$11.93 | CA$15.53 | x |
| 2025-12-31 | CA$14.92 | CA$15.53 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Big Pharma Split Corp Class A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 24.09%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 302.72%
- • Asset Turnover: 0.05x
- • Equity Multiplier: 1.74x
- Recent ROE (24.09%) is above the historical average (12.35%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 1.73% | 79.39% | 0.01x | 1.74x | CA$-1.54 Million |
| 2018 | 14.75% | 86.01% | 0.10x | 1.78x | CA$895.79K |
| 2019 | 35.77% | 239.67% | 0.09x | 1.67x | CA$4.20 Million |
| 2020 | 2.01% | 45.04% | 0.03x | 1.74x | CA$-1.05 Million |
| 2021 | 21.66% | 90.56% | 0.14x | 1.69x | CA$2.61 Million |
| 2022 | 15.94% | 84.77% | 0.09x | 1.98x | CA$1.17 Million |
| 2023 | -0.88% | -44.80% | 0.01x | 1.67x | CA$-1.72 Million |
| 2024 | -3.94% | -29.13% | 0.07x | 1.92x | CA$-1.91 Million |
| 2025 | 24.09% | 302.72% | 0.05x | 1.74x | CA$2.57 Million |
Industry Comparison
This section compares Big Pharma Split Corp Class A's net assets metrics with peer companies in the Asset Management industry.
Industry Context
- Industry: Asset Management
- Average net assets among peers: $17,012,400,815
- Average return on equity (ROE) among peers: 9.03%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Big Pharma Split Corp Class A (PRM) | CA$19.44 Million | 1.73% | 0.72x | $14.75 Million |
| Aberdeen International Inc. (AAB) | $28.67 Million | 6.52% | 0.06x | $1.74 Million |
| Base Carbon Inc. (BCBN) | $52.38 Million | -2.92% | 0.01x | $41.59 Million |
| Canadian Banc Corp (BK) | $98.80 Million | 12.59% | 0.84x | $524.68 Million |
| Brookfield Corporation (BN) | $165.38 Billion | 0.39% | 1.97x | $92.30 Billion |
| Sprott Physical Gold and Silver Trust (CEF) | $541.00 Million | 7.88% | 0.00x | $6.99 Billion |
| Canadian General Investments Ltd (CGI) | $1.16 Billion | 15.01% | 0.15x | $763.28 Million |
| CI Financial Corp (CIX) | $1.90 Billion | 29.18% | 0.74x | $3.32 Billion |
| Culico Metals Inc. (CLCO) | $0.00 | 0.00% | 0.00x | $23.65 Million |
| Clairvest Group Inc. (CVG) | $234.44 Million | 5.47% | 0.29x | $842.02 Million |
| Cymbria Corporation (CYB) | $728.31 Million | 16.15% | 0.06x | $1.15 Billion |
About Big Pharma Split Corp Class A
Big Pharma Split Corp is a closed ended equity mutual fund launched and managed by Harvest Portfolios Group Inc. It invests in the public equity markets across United States. The fund primarily invests in the Pharmaceutical sector. Big Pharma Split Corp was formed on September 15, 2017 and is domiciled in Canada.